Identification of genes involved in the sensitivity to antitumour drug 17-allylamino,17-demethoxygeldanamycin (17AAG).
In the present study we analysed the gene expression database provided by the National Cancer Institute in an attempt to correlate activity profiles of geldanamycin, 17AAG and 11 other analogues in 60 human tumor cell lines with their gene expression profiles determined by the cDNA microarray technique. On the basis of the activity profiles two classes of geldanamycin analogues could be distinguished, having geldanamycin and 17AAG, respectively, as prototype compounds (denominated as gelda-like and 17AAG-like classes). Application of the "soft" statistical methodology of PLS (partial least squares modelling in latent variables or projections to latent structures) allowed us to evaluate the influence of each gene expression target in determining the therapeutical responses. The transcript encoding the translocating chain-associated membrane protein (TRAM) showed a significant statistical correlation with activity profiles of 17AAG. In order to validate the role of TRAM in determining sensitivity to 17AAG we induced a selective knocking-down of this transcript by the RNA interference methodology in H226 non-small cell lung carcinoma cell line. The efficiency of double-stranded RNA oligonucleotides (short-interfering RNAs, siRNAs) was determined by measuring TRAM mRNA levels by quantitative real-time RT-PCR at different times (24-72 hours) after siRNA lipotransfection. A significant increase in chemosensitivity to 17AAG was observed in siRNA-silenced cells. Although a number of factors may affect tumour sensitivity to 17AAG the present methodology allowed us to dissect out a single parameter which may be partly responsible for its activity.
Barresi
Vincenza
V
Dipartimento di Scienze Chimiche, Università di Catania, 95125 Catania, Italy.
Fortuna
Cosimo G
CG
Garozzo
Roberta
R
Musumarra
Giuseppe
G
Scirè
Salvatore
S
Condorelli
Daniele F
DF
D000970:Antineoplastic Agents / Q000627:therapeutic use; D016227:Benzoquinones / Q000627:therapeutic use*; D049109:Cell Proliferation / Q000187:drug effects; D020869:Gene Expression Profiling; D006801:Humans; D020128:Inhibitory Concentration 50; D047029:Lactams, Macrocyclic / Q000627:therapeutic use*; D008562:Membrane Glycoproteins / Q000378:metabolism / Q000502:physiology; D008954:Models, Biological; D015999:Multivariate Analysis; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000502:physiology; D014162:Transfection; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D016227:Benzoquinones; D047029:Lactams, Macrocyclic; D008562:Membrane Glycoproteins; D034741:RNA, Small Interfering; C074282:translocating chain-associating membrane protein (TRAM); C112765:tanespimycin; C001277:geldanamycin